GoKawiilStudy probes why 10-15% of patients don't lose weight on GLP-1 drugs
Researchers report that while most people on GLP-1 obesity drugs lose about a quarter of their body weight, 10-15% see minimal or no weight loss, according to endocrinologist Daniel Drucker of the University of Toronto. The Endocrine Society has called understanding this variation a research priority, citing early findings that biological sex, genetics and behavioral factors may all play a role, with women consistently losing more weight than men in trials and real-world data.
GoKawiil's interpretation of the reporting above, not reported fact.
Identifying why some patients don't respond could open the door to new obesity drugs and allow doctors to match patients to treatments more likely to work for them, though the Endocrine Society itself describes such precision medicine as still largely aspirational. The sex-based difference in response suggests biological factors like hormones may influence drug effectiveness, which could eventually shape how GLP-1 drugs are prescribed or dosed.
- 10-15% of people on GLP-1 obesity drugs experience little to no weight loss despite average losses of 25% body weight in others.
- Women consistently lose more weight than men on these drugs in both clinical trials and real-world data.
- The Endocrine Society has flagged personalized response to GLP-1s as a key research priority, though precision treatment remains largely theoretical for now.
Source: nature.com — Lenharo, 2026-09-24
Published there as: “GLP-1 drugs fail to help some people lose weight — scientists are on a quest for answers”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.